We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma.
- Authors
Cai, Yu; Wan, Liping; Yang, Juan; Zhu, Jun; Jiang, Jieling; Li, Su; Song, Xianmin; Wang, Chun
- Abstract
To evaluate the strategy of using high-dose etoposide mobilization followed by autologous peripheral blood stem cell transplantation (APBSCT) in patients with diffuse large B cell lymphoma (DLBCL) refractory to rituximab-based chemotherapy. Forty patients with refractory DLBCL were treated with high-dose etoposide for stem cell mobilization. All patients were in progressive disease (PD) prior to mobilization and underwent high-dose chemotherapy followed by APBSCT. Successful PBSC mobilization was achieved in all patients. Twenty-three patients (57.5%) showed a clinical response to high-dose etoposide. After APBSCT, 17 patients (42.5%) achieved CR. The 2-year progression-free (PFS) and overall survival (OS) rate were higher in patients responding to high-dose etoposide (64.1% and 77.7%) compared to those without response (11.8% and 11.8%; P < 0.001 for both). The response to high-dose etoposide mobilization therapy was an independent prognostic factor for CR achievement, PFS and OS after APBSCT. High-dose etoposide mobilization chemotherapy followed by APBSCT could rescue a proportion of patients with refractory DLBCL who responded to etoposide mobilization regimen.
- Subjects
STEM cell transplantation; B cells; BLOOD cells; AUTOGRAFTS; B cell lymphoma; BIOTHERAPY; DRUG resistance in cancer cells; ETOPOSIDE; HEMATOPOIETIC stem cell transplantation; LONGITUDINAL method; PROGNOSIS
- Publication
Annals of Hematology, 2019, Vol 98, Issue 4, p823
- ISSN
0939-5555
- Publication type
journal article
- DOI
10.1007/s00277-019-03605-1